Continue to Site

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » MDxHealth wins $1.1 million European grant for cancer research | Funding roundup

MDxHealth wins $1.1 million European grant for cancer research | Funding roundup

By

Funding

Personalized medicine firm MDxHealth SA (BSE:MDXH.BR) and its research partner NovioGendix B.V. won a $1.1 million grant to support the research and development of a new bladder cancer diagnostic.

The funding came from Eurotrans-Bio, a European Commission initiative that supports biotech R&D between companies and academia.

Belgium-based MDxHealth, which has U.S. headquarters in Durham, N.C., develops companion diagnostics for cancer treatments and NovioGendix is a molecular diagnostics firm that was spun out of Radboud University Nigmegen Medical Centre in the Netherlands.

The grant provides both companies with the resources to further investigate the biological indicators and patterns seen in bladder cancer, according to MDxHealth. The companies hope discover and validate tumor markers, which will guide treatment decisions, with patient samples collected from an existing collaboration between the two firms.

The companies said there is an urgent need for accurate biomarkers of bladder cancer so diagnostic tests can be developed for earlier, and personalized, therapeutic intervention.

MDxHealth was founded in 2003 as OncoMethylome Sciences to develop companion diagnostics that could help physicians diagnose and treat cancer. The company last October changed its name to MDxHealth as part of strategy shift from out-licensing its biomarker discoveries to instead developing and commercializing those discoveries on its own.

MDxHealth last month raised $11.7 million in a private placement of securities that included an investment from Belgian life sciences entrepreneur and investor Rudi Marien, whose investment firm Biovest secured a 9 percent stake in the company.

Here’s a roundup of the latest dealflow and investment news:

  • NIH grants Immunetics $2.4 million for Chagas’ disease blood test trials
    Immunetics Inc. announced it has been awarded a $2.4 million, 3-year Phase II SBIR grant by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, to support clinical trials of the company’s new confirmatory test for Chagas’ disease, a serious and potentially fatal parasitic infection.
    Read more

  • OrSense drums up $18 million
    OrSense Ltd., developer of monitors for non-invasive measurements of key blood parameters, announced the closing of a $18 million financing led by Israel Healthcare Ventures (IHCV). Participating venture capital organizations include current investors: IHCV, STAR Ventures and Lewis Trust Private Equity division. The funds raised will be used to accelerate commercialization activities of the Company’s products for non-invasive monitoring of various blood parameters.
    Read more

  • Stealthy neurotech startup NeuroVigil closes first round
    NeuroVigil Inc., a San Diego-based neurotechnology company, announced it closed its first round of financing. NeuroVigil’s first round was at a pre-investment valuation reportedly over twice the combined seed valuations of Google Inc. and Facebook’s first rounds, and for less than 2 percent of the company’s stock. The round was led by an anonymous American industrialist and technology visionary, with participants distributed across both the U.S. West and East Coasts, the company said.
    Read more

  • BioBehavioral Diagnostics aims for $500,000
    BioBehavioral Diagnostics Co. raised $300,000 and is hoping for another $200,000. The debt and options-based financing was supported by three unnamed investors. The Westford, Mass.-based company makes a medical device for attention deficit hyperactivity disorder (ADHD).
    Read more

  • Elekta issues new shares
    Elekta AB (publ) issued 33,042 new B shares in April through the exercise of warrants distributed within the framework of an established option program. The total number of shares in Elekta as of April 29, 2011 amounts to 94,239,669 divided between 3,562,500 A shares and 90,677,169 B shares. One A share entitles the holder to ten votes and one B shares to one vote. The above information is such that Elekta shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act
    Read more

  • Xlumena completes $7 million B round
    Xlumena, a privately held provider of technology for the interventional endoscopist and endoscopic surgeon, closed its Series B financing. The current round of financing was led by new investor, Aperture Venture Partners, LLC and joined by Western Technology Investment. In conjunction with the financing, Eric Sillman of Aperture Venture Partners and Dr. Avi Kometz of Ascent Biomedical Ventures will join Xlumena’s board. Also participating in the current round of financing were existing institutional investors Prism Ventures, Charter Life Sciences and Ascent Biomedical Ventures.
    Read more

  • Bankrupt Angiotech announces another debt exchange extension
    Angiotech Pharmaceuticals Inc. extended its offer to exchange new senior secured floating rate notes due 2013 for all of its outstanding Senior Floating Rate Notes due 2013 to 12:00 a.m. New York City time on May 12. The offer was last scheduled to expire at 11:59 p.m. New York City time on May 9. The extension of the exchange offer has been made to allow holders of outstanding Existing Floating Rate Notes who have not yet tendered their Existing Floating Rate Notes for exchange to do so.
    Read more

  • Bacterin secures $1.9 million through private placement
    Bacterin International Holdings Inc. (NYSE Amex:BONE) announced that, subject to NYSE Amex approval, it has raised $1.9 million in a private placement transaction. The transaction was funded in two tranches and priced at market value on the date each tranche was submitted to NYSE Amex for approval. In addition to shares of common stock, investors also received warrants to purchase 40 percent of the common shares purchased in the private placement at the closing price. The warrants are exercisable over the next five years, subject to a six month holding period. Bacterin intends to use proceeds from the private placement for working capital and to increase production capacity in light of growing demand for its existing and newly launched products.
    Read more

Material from MedCity News was used in this report.

In case you missed it

RSS From Medical Design & Outsourcing

  • Cardinal Health CEO becomes one of medtech’s top-paid executives
    Cardinal Health disclosed pay and perks for other leaders and its median employee, as well as severance payouts for two former top executives. Cardinal Health paid CEO Jason Hollar nearly $18.8 million in his first year on the job, the device manufacturer and pharmaceutical distrbutor said in a new executive pay disclosure. That makes Hollar… […]
  • Biomerics completes expansion in Minnesota
    NEWS RELEASE: Biomerics announces completion of 100,000 ft² expansion of Brooklyn Park, Minnesota, facility Salt Lake City (Sept. 22, 2023 ) – Biomerics , the leading vertically integrated medical device contract manufacturer in the interventional device market, announced the completion of a 100,000 ft² expansion of its operations in Brooklyn Park, Minnesota, bringing the facility… […]
  • Cadence acquires ARC Group Worldwide’s Florida location
    NEWS RELEASE: Cadence acquires ARC Group Worldwide’s Florida location Staunton, Virginia (October 3, 2023) – Cadence, Inc., a leading provider of design, development, and contract manufacturing services to the medical device, drug delivery, and diagnostics markets, announced today that it has acquired the Florida location of ARC Group Worldwide (arcw.com), a precision manufacturer specializing in metal… […]
  • MGS acquires medical toolmaker Winther Mould Technology
    NEWS RELEASE: MGS acquires experienced medical toolmaker Winther Mould Technology Integrated healthcare manufacturer expands tooling capacity while strengthening global position. GERMANTOWN, Wis. (October 2, 2023) – MGS, a global leader in end-to-end manufacturing solutions for healthcare innovators, announced today the acquisition of healthcare tooling manufacturer, Winther Mould Technology A/S (“Winther Mould”). The investment in additional… […]
  • NAMSA opens expanded preclinical lab near Minneapolis
    North American Science Associates (NAMSA) recently opened its expanded preclinical lab near Minneapolis. It is “the biggest worldwide preclinical facility dedicated to medical medtech services,” NAMSA CEO Christophe Berthoux said in a promotional video by Medical Alley. The facility — at 8945 Evergreen Boulevard in Coon Rapids, Minnesota — now has six cath labs and… […]
  • Resonetics closes $900M nitinol deal and rebrands Memry and Smart Materials
    Resonetics has closed on its $900 million acquisition of the SAES Getters medical nitinol business. Nashua, New Hampshire–based Resonetics said it will rebrand Memry Corporation and SAES Smart Materials as Resonetics. The Smart Materials business creates raw nitinol alloy from nickel and titanium and produces nitinol wires, bars, ribbons and sheets. The Memry business offers electric… […]
  • Ananya Health wants to bring battery-powered cryoablation to the global fight against cancer
    Cervical cancer is the fourth most common cancer among women and has a high mortality rate globally, according to the World Health Organization. Screening and effective interventions can reduce cervical cancer deaths, but that access is limited in emerging markets and developing countries. Ananya Health, co-founded by Anu Parvatiyar, is at the forefront of tackling… […]
  • Engineering Medical Devices with Biocompatibility in Mind
    By Michael Alabran, President of PSN Labs Characterizing the risks of medical devices has always been a challenge. Materials are at the core of this challenge, especially as supply chain disruptions have led to the need to alter materials to continue production of critical devices. The understanding of toxicology and the effect of chemistry on… […]
  • “Maybe we’re overthinking it” — A tough call was the right call for this medtech developer
    The challenges of developing the LimFlow System for Transcatheter Arterialization of Deep Veins (TADV) went beyond engineering and anatomical obstacles. One of the biggest hurdles was downright emotional, LimFlow leaders said in an interview with Medical Design & Outsourcing. Artery-to-vein crossing is key to LimFlow’s unique FDA-approved system for chronic limb-threatening ischemia (CLTI) patients who… […]
  • FDA proposes boosted regulations of lab-developed tests
    The FDA today announced a proposed rule that would make it explicit that in vitro diagnostics are medical devices under the Federal Food, Drug, and Cosmetic Act, including when the manufacturer of the IVD is a laboratory. The agency is publishing the full rule proposal in the Federal Register. “A growing number of clinical diagnostic… […]
  • Navigating thermally induced dynamics when developing miniaturized medical devices
    Understanding and managing thermally induced dynamics during assembly and use is essential as devices become increasingly integrated and miniaturized. By Dave Fromm, Promex Some complexities of integrating miniaturized components, such as microelectronics, into increasingly small medical devices are obvious. Examples include the precision required to position and align components with the requisite accuracy, or the… […]

Copyright © 2023 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy